Lp(a) (Lipoprotein(a)) Levels Predict Progression of Carotid Atherosclerosis in Subjects With Atherosclerotic Cardiovascular Disease on Intensive Lipid Therapy: An Analysis of the AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Outcomes) Carotid Magnetic Resonance Imaging Substudy—Brief Report
OBJECTIVE—To assess whether Lp(a) (lipoprotein(a)) levels and other lipid levels were predictive of progression of atherosclerosis burden as assessed by carotid magnetic resonance imaging in subjects who have been treated with LDL-C (low-density lipoprotein cholesterol)–lowering therapy and particip...
Saved in:
Published in | Arteriosclerosis, thrombosis, and vascular biology Vol. 38; no. 3; pp. 673 - 678 |
---|---|
Main Authors | , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
American Heart Association, Inc
01.03.2018
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | OBJECTIVE—To assess whether Lp(a) (lipoprotein(a)) levels and other lipid levels were predictive of progression of atherosclerosis burden as assessed by carotid magnetic resonance imaging in subjects who have been treated with LDL-C (low-density lipoprotein cholesterol)–lowering therapy and participated in the AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High TriglyceridesImpact on Global Health Outcomes).
APPROACH AND RESULTS—AIM-HIGH was a randomized, double-blind study of subjects with established vascular disease, elevated triglycerides, and low HDL-C (high-density lipoprotein cholesterol). One hundred fifty-two AIM-HIGH subjects underwent both baseline and 2-year follow-up carotid artery magnetic resonance imaging. Plaque burden was measured by the percent wall volume (%WV) of the carotid artery. Associations between annualized change in %WV with baseline and on-study (1 year) lipid variables were evaluated using multivariate linear regression and the Bonferroni correction to account for multiple comparisons. Average %WV at baseline was 41.6±6.8% and annualized change in %WV over 2 years ranged from −3.2% to 3.7% per year (mean0.2±1.1% per year; P=0.032). Increases in %WV were significantly associated with higher baseline Lp(a) (β=0.34 per 1-SD increase of Lp(a); 95% confidence interval, 0.15–0.52; P<0.001) after adjusting for clinical risk factors and other lipid levels. On-study Lp(a) had a similar positive association with %WV progression (β=0.33; 95% confidence interval, 0.15–0.52; P<0.001).
CONCLUSIONS—Despite intensive lipid therapy, aimed at aggressively lowering LDL-C to <70 mg/dL, carotid atherosclerosis continued to progress as assessed by carotid magnetic resonance imaging and that elevated Lp(a) levels were independent predictors of increases in atherosclerosis burden. |
---|---|
AbstractList | To assess whether Lp(a) (lipoprotein(a)) levels and other lipid levels were predictive of progression of atherosclerosis burden as assessed by carotid magnetic resonance imaging in subjects who have been treated with LDL-C (low-density lipoprotein cholesterol)-lowering therapy and participated in the AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Outcomes).OBJECTIVETo assess whether Lp(a) (lipoprotein(a)) levels and other lipid levels were predictive of progression of atherosclerosis burden as assessed by carotid magnetic resonance imaging in subjects who have been treated with LDL-C (low-density lipoprotein cholesterol)-lowering therapy and participated in the AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Outcomes).AIM-HIGH was a randomized, double-blind study of subjects with established vascular disease, elevated triglycerides, and low HDL-C (high-density lipoprotein cholesterol). One hundred fifty-two AIM-HIGH subjects underwent both baseline and 2-year follow-up carotid artery magnetic resonance imaging. Plaque burden was measured by the percent wall volume (%WV) of the carotid artery. Associations between annualized change in %WV with baseline and on-study (1 year) lipid variables were evaluated using multivariate linear regression and the Bonferroni correction to account for multiple comparisons. Average %WV at baseline was 41.6±6.8% and annualized change in %WV over 2 years ranged from -3.2% to 3.7% per year (mean: 0.2±1.1% per year; P=0.032). Increases in %WV were significantly associated with higher baseline Lp(a) (β=0.34 per 1-SD increase of Lp(a); 95% confidence interval, 0.15-0.52; P<0.001) after adjusting for clinical risk factors and other lipid levels. On-study Lp(a) had a similar positive association with %WV progression (β=0.33; 95% confidence interval, 0.15-0.52; P<0.001).APPROACH AND RESULTSAIM-HIGH was a randomized, double-blind study of subjects with established vascular disease, elevated triglycerides, and low HDL-C (high-density lipoprotein cholesterol). One hundred fifty-two AIM-HIGH subjects underwent both baseline and 2-year follow-up carotid artery magnetic resonance imaging. Plaque burden was measured by the percent wall volume (%WV) of the carotid artery. Associations between annualized change in %WV with baseline and on-study (1 year) lipid variables were evaluated using multivariate linear regression and the Bonferroni correction to account for multiple comparisons. Average %WV at baseline was 41.6±6.8% and annualized change in %WV over 2 years ranged from -3.2% to 3.7% per year (mean: 0.2±1.1% per year; P=0.032). Increases in %WV were significantly associated with higher baseline Lp(a) (β=0.34 per 1-SD increase of Lp(a); 95% confidence interval, 0.15-0.52; P<0.001) after adjusting for clinical risk factors and other lipid levels. On-study Lp(a) had a similar positive association with %WV progression (β=0.33; 95% confidence interval, 0.15-0.52; P<0.001).Despite intensive lipid therapy, aimed at aggressively lowering LDL-C to <70 mg/dL, carotid atherosclerosis continued to progress as assessed by carotid magnetic resonance imaging and that elevated Lp(a) levels were independent predictors of increases in atherosclerosis burden.CONCLUSIONSDespite intensive lipid therapy, aimed at aggressively lowering LDL-C to <70 mg/dL, carotid atherosclerosis continued to progress as assessed by carotid magnetic resonance imaging and that elevated Lp(a) levels were independent predictors of increases in atherosclerosis burden. To assess whether Lp(a) (lipoprotein(a)) levels and other lipid levels were predictive of progression of atherosclerosis burden as assessed by carotid magnetic resonance imaging in subjects who have been treated with LDL-C (low-density lipoprotein cholesterol)-lowering therapy and participated in the AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Outcomes). AIM-HIGH was a randomized, double-blind study of subjects with established vascular disease, elevated triglycerides, and low HDL-C (high-density lipoprotein cholesterol). One hundred fifty-two AIM-HIGH subjects underwent both baseline and 2-year follow-up carotid artery magnetic resonance imaging. Plaque burden was measured by the percent wall volume (%WV) of the carotid artery. Associations between annualized change in %WV with baseline and on-study (1 year) lipid variables were evaluated using multivariate linear regression and the Bonferroni correction to account for multiple comparisons. Average %WV at baseline was 41.6±6.8% and annualized change in %WV over 2 years ranged from -3.2% to 3.7% per year (mean: 0.2±1.1% per year; =0.032). Increases in %WV were significantly associated with higher baseline Lp(a) (β=0.34 per 1-SD increase of Lp(a); 95% confidence interval, 0.15-0.52; <0.001) after adjusting for clinical risk factors and other lipid levels. On-study Lp(a) had a similar positive association with %WV progression (β=0.33; 95% confidence interval, 0.15-0.52; <0.001). Despite intensive lipid therapy, aimed at aggressively lowering LDL-C to <70 mg/dL, carotid atherosclerosis continued to progress as assessed by carotid magnetic resonance imaging and that elevated Lp(a) levels were independent predictors of increases in atherosclerosis burden. OBJECTIVE—To assess whether Lp(a) (lipoprotein(a)) levels and other lipid levels were predictive of progression of atherosclerosis burden as assessed by carotid magnetic resonance imaging in subjects who have been treated with LDL-C (low-density lipoprotein cholesterol)–lowering therapy and participated in the AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High TriglyceridesImpact on Global Health Outcomes). APPROACH AND RESULTS—AIM-HIGH was a randomized, double-blind study of subjects with established vascular disease, elevated triglycerides, and low HDL-C (high-density lipoprotein cholesterol). One hundred fifty-two AIM-HIGH subjects underwent both baseline and 2-year follow-up carotid artery magnetic resonance imaging. Plaque burden was measured by the percent wall volume (%WV) of the carotid artery. Associations between annualized change in %WV with baseline and on-study (1 year) lipid variables were evaluated using multivariate linear regression and the Bonferroni correction to account for multiple comparisons. Average %WV at baseline was 41.6±6.8% and annualized change in %WV over 2 years ranged from −3.2% to 3.7% per year (mean0.2±1.1% per year; P=0.032). Increases in %WV were significantly associated with higher baseline Lp(a) (β=0.34 per 1-SD increase of Lp(a); 95% confidence interval, 0.15–0.52; P<0.001) after adjusting for clinical risk factors and other lipid levels. On-study Lp(a) had a similar positive association with %WV progression (β=0.33; 95% confidence interval, 0.15–0.52; P<0.001). CONCLUSIONS—Despite intensive lipid therapy, aimed at aggressively lowering LDL-C to <70 mg/dL, carotid atherosclerosis continued to progress as assessed by carotid magnetic resonance imaging and that elevated Lp(a) levels were independent predictors of increases in atherosclerosis burden. |
Author | O’Brien, Kevin D. Anderson, Todd Hatsukami, Thomas S. Crouse, John R. Phan, Binh P. Isquith, Daniel A. Hippe, Daniel S. Huston, John Sun, Jie Marcovina, Santica M. Yuan, Chun Zhao, Xue-Qiao |
AuthorAffiliation | From the Department of Radiology (D.S.H., J.S., C.Y.), Division of Cardiology (D.A.I., K.D.O., X.-Q.Z.), and Department of Surgery, Division of Vascular Surgery (T.S.H.), University of Washington School of Medicine, Seattle; Division of Cardiology, San Francisco General Hospital, University of California (B.A.P.P.); Department of Medicine, Wake Forest School of Medicine, Winston-Salem, NC (J.R.C.); Libin Cardiovascular Institute of Alberta, University of Calgary, Canada (T.A.); Department of Radiology, Mayo Clinic, Rochester, MN (J.H.); and Northwest Lipid Metabolism and Diabetes Research Laboratories, University of Washington, Seattle (S.M.M.) |
AuthorAffiliation_xml | – name: From the Department of Radiology (D.S.H., J.S., C.Y.), Division of Cardiology (D.A.I., K.D.O., X.-Q.Z.), and Department of Surgery, Division of Vascular Surgery (T.S.H.), University of Washington School of Medicine, Seattle; Division of Cardiology, San Francisco General Hospital, University of California (B.A.P.P.); Department of Medicine, Wake Forest School of Medicine, Winston-Salem, NC (J.R.C.); Libin Cardiovascular Institute of Alberta, University of Calgary, Canada (T.A.); Department of Radiology, Mayo Clinic, Rochester, MN (J.H.); and Northwest Lipid Metabolism and Diabetes Research Laboratories, University of Washington, Seattle (S.M.M.) |
Author_xml | – sequence: 1 givenname: Daniel surname: Hippe middlename: S. fullname: Hippe, Daniel S. organization: From the Department of Radiology (D.S.H., J.S., C.Y.), Division of Cardiology (D.A.I., K.D.O., X.-Q.Z.), and Department of Surgery, Division of Vascular Surgery (T.S.H.), University of Washington School of Medicine, Seattle; Division of Cardiology, San Francisco General Hospital, University of California (B.A.P.P.); Department of Medicine, Wake Forest School of Medicine, Winston-Salem, NC (J.R.C.); Libin Cardiovascular Institute of Alberta, University of Calgary, Canada (T.A.); Department of Radiology, Mayo Clinic, Rochester, MN (J.H.); and Northwest Lipid Metabolism and Diabetes Research Laboratories, University of Washington, Seattle (S.M.M.) – sequence: 2 givenname: Binh surname: Phan middlename: P. fullname: Phan, Binh P. – sequence: 3 givenname: Jie surname: Sun fullname: Sun, Jie – sequence: 4 givenname: Daniel surname: Isquith middlename: A. fullname: Isquith, Daniel A. – sequence: 5 givenname: Kevin surname: O’Brien middlename: D. fullname: O’Brien, Kevin D. – sequence: 6 givenname: John surname: Crouse middlename: R. fullname: Crouse, John R. – sequence: 7 givenname: Todd surname: Anderson fullname: Anderson, Todd – sequence: 8 givenname: John surname: Huston fullname: Huston, John – sequence: 9 givenname: Santica surname: Marcovina middlename: M. fullname: Marcovina, Santica M. – sequence: 10 givenname: Thomas surname: Hatsukami middlename: S. fullname: Hatsukami, Thomas S. – sequence: 11 givenname: Chun surname: Yuan fullname: Yuan, Chun – sequence: 12 givenname: Xue-Qiao surname: Zhao fullname: Zhao, Xue-Qiao |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/29301785$$D View this record in MEDLINE/PubMed |
BookMark | eNp9Ul1v0zAUDWiIfcAf4AH5sX3oZidNmuwt62CplGmIFXiMHOem9XDtYDud-saP4BfyS7hZxyR4mGTZvtI5x-f63OPgQBsNQfCO0VPGEnaWL79e5EWOxew0YjRK0pfBEYvD6WSaRMkB3uksm8TJNDwMjp27o5ROw5C-Dg7DLKJslsZHL0zZjfiYjErZmc4aD1JjPSYlbEE58slCI4XH06wsOCeNJqYlc45Q2ZDcr8EaJ9SwS0ekJrd9fQfCO_JN-vU_AC_FQGyk2XInesUtuZQOuAOCqgvtQTu5BYJWUHqJRN7tzkmucXG1G_TxaRQk-eJ6UiyuCjLa6_u1NZv6wcEgY7eg_eAU7VyD57VR-PTtTjcIg72x0tyT4rI8K-RqTZZWrtROgJUNuHOy2HQce0aBK2VqrkgBXCHnpvcCBdz4qf9rvtIw9PUZnNFcC0AyX0m9Gv7B-b7Z_f7568JKaBHSGevfBK9arhy8fTxPgi8fPyznxaS8uVrM83IiwiROJ-1sFrM6ok0LLQ1ZG0VNmIFgWRbFouZ0SiGJWJzUbUYbNg1TgAQaFoqUxnHdsOgkGO11MdQfPThfbaQToBTXYHpXsSzN4iilbIC-f4T29QaaqrNyw-2u-jskCAj3AIFROgvtE4TRapjE6nESsZhV-0lEUvofSUjPh1i85VI9T0321HujME33XfX3YKv1QwrPEf8AzYL79Q |
CitedBy_id | crossref_primary_10_1016_j_atherosclerosis_2018_08_037 crossref_primary_10_1016_j_addr_2020_07_019 crossref_primary_10_1016_j_pcad_2020_04_004 crossref_primary_10_1177_10760296221121282 crossref_primary_10_1161_CIRCULATIONAHA_120_052023 crossref_primary_10_1016_j_ihj_2019_03_004 crossref_primary_10_1016_j_amjcard_2024_09_006 crossref_primary_10_3390_jcdd8020011 crossref_primary_10_1016_j_clinsp_2022_100107 crossref_primary_10_1097_MOL_0000000000000889 crossref_primary_10_1007_s11883_019_0773_y crossref_primary_10_1093_eurjpc_zwab052 crossref_primary_10_1080_10641963_2019_1619754 crossref_primary_10_1016_j_acvd_2024_07_061 crossref_primary_10_1080_10408363_2025_2462817 crossref_primary_10_1161_STROKEAHA_120_030616 crossref_primary_10_1016_j_pharmthera_2020_107592 crossref_primary_10_1038_s41467_021_21390_2 crossref_primary_10_1016_j_atherosclerosis_2021_05_008 crossref_primary_10_1161_ATVBAHA_120_313609 crossref_primary_10_36485_1561_6274_2021_25_1_31_46 crossref_primary_10_18087_cardio_2019_12_n727 crossref_primary_10_1186_s12872_021_02038_x crossref_primary_10_1016_j_amjmed_2018_08_019 crossref_primary_10_3389_fcvm_2021_742935 crossref_primary_10_1161_ATVBAHA_118_312267 crossref_primary_10_1016_j_arcmed_2020_12_003 crossref_primary_10_3390_ijerph20186721 crossref_primary_10_1161_ATVBAHA_118_311999 crossref_primary_10_1161_ATVBAHA_119_312001 crossref_primary_10_3390_ijms222111419 |
Cites_doi | 10.1161/STROKEAHA.113.001461 10.1001/jama.1987.03390230069027 10.1016/j.amjcard.2014.08.001 10.1161/ATVBAHA.112.251306 10.1016/j.jacc.2013.06.051 10.1161/STROKEAHA.111.624684 10.1194/jlr.R052258 10.1056/NEJMoa011090 10.1056/NEJM199011083231901 10.7326/0003-4819-142-2-200501180-00008 10.1161/STROKEAHA.114.005752 10.1093/eurheartj/ehq386 10.1161/CIRCULATIONAHA.107.715698 10.1016/j.jacc.2010.03.017 10.1001/jama.2009.1063 10.1016/j.atherosclerosis.2017.06.026 10.1056/NEJMoa0902604 10.1016/j.atherosclerosis.2015.11.032 10.1056/NEJMoa1501031 10.1194/jlr.P030890 10.1056/NEJMoa1615664 10.1161/01.CIR.102.10.1082 10.1161/01.CIR.0000148955.19792.8D 10.1038/ncpcardio1456 10.1194/jlr.M040733 10.1056/NEJMoa1500858 10.2217/clp.13.9 10.1016/j.amjcard.2014.01.426 10.1001/jama.2016.16951 10.1001/jama.2009.801 10.1056/NEJMoa1107579 |
ContentType | Journal Article |
Copyright | 2018 American Heart Association, Inc. |
Copyright_xml | – notice: 2018 American Heart Association, Inc. |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 |
DOI | 10.1161/ATVBAHA.117.310368 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1524-4636 |
EndPage | 678 |
ExternalDocumentID | 29301785 10_1161_ATVBAHA_117_310368 10.1161/ATVBAHA.117.310368 |
Genre | Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
GrantInformation_xml | – fundername: NIDDK NIH HHS grantid: P30 DK017047 – fundername: NHLBI NIH HHS grantid: R01 HL088214 – fundername: NHLBI NIH HHS grantid: R01 HL063895 – fundername: NHLBI NIH HHS grantid: T32 HL007828 |
GroupedDBID | --- .3C .55 .GJ .Z2 01R 0R~ 1J1 23N 2WC 3O- 40H 4Q1 4Q2 4Q3 53G 5GY 5RE 5VS 71W 77Y 7O~ AAAAV AAAXR AAGIX AAHPQ AAIQE AAMOA AAMTA AAQKA AARTV AASCR AASOK AAXQO ABASU ABBUW ABDIG ABJNI ABPXF ABQRW ABVCZ ABXVJ ABZAD ABZZY ACCJW ACDDN ACEWG ACGFS ACGOD ACILI ACLDA ACPRK ACWDW ACWRI ACXJB ACXNZ ACZKN ADBBV ADFPA ADGGA ADHPY ADNKB AE3 AE6 AEETU AENEX AFBFQ AFDTB AFFNX AFUWQ AGINI AHJKT AHMBA AHOMT AHQNM AHRYX AHVBC AIJEX AINUH AJCLO AJIOK AJNWD AJNYG AJZMW AKCTQ AKULP ALKUP ALMA_UNASSIGNED_HOLDINGS ALMTX AMJPA AMKUR AMNEI AOHHW AOQMC AYCSE BAWUL BOYCO BQLVK BS7 C1A C45 CS3 DIK DIWNM DUNZO E.X E3Z EBS EEVPB EJD ERAAH EX3 F2K F2L F2M F2N F5P FCALG FL- FRP FW0 GNXGY GQDEL GX1 H0~ H13 HLJTE HZ~ IKREB IKYAY IN~ IPNFZ J5H JF9 JG8 JK3 JK8 K8S KD2 KMI KQ8 L-C L7B N9A N~7 N~B N~M O9- OAG OAH OB2 OCUKA ODA OL1 OLG OLH OLU OLV OLY OLZ OPUJH ORVUJ OUVQU OVD OVDNE OVIDH OVLEI OWU OWV OWW OWX OWY OWZ OXXIT P-K P2P PQQKQ PZZ RAH RIG RLZ S4R S4S T8P TEORI TR2 TSPGW V2I VVN W3M W8F WOQ WOW X3V X3W X7M XXN XYM YFH ZGI ZZMQN AAYXX ADGHP CITATION ACIJW AWKKM CGR CUY CVF ECM EIF NPM OK1 OLW RHF 7X8 |
ID | FETCH-LOGICAL-c2658-f7751b30dfef021f33d29ec19935cba040e63156bf90d1428ee6ed12c8055bd13 |
ISSN | 1079-5642 1524-4636 |
IngestDate | Fri Jul 11 07:41:57 EDT 2025 Wed Feb 19 02:31:25 EST 2025 Thu Apr 24 22:58:08 EDT 2025 Tue Jul 01 02:21:59 EDT 2025 Fri May 16 03:42:25 EDT 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 3 |
Keywords | atherosclerosis lipids risk factors lipoprotein lp(a) triglycerides lipoprotein(a) |
Language | English |
License | 2018 American Heart Association, Inc. |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c2658-f7751b30dfef021f33d29ec19935cba040e63156bf90d1428ee6ed12c8055bd13 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 |
PMID | 29301785 |
PQID | 1989538011 |
PQPubID | 23479 |
PageCount | 6 |
ParticipantIDs | proquest_miscellaneous_1989538011 pubmed_primary_29301785 crossref_primary_10_1161_ATVBAHA_117_310368 crossref_citationtrail_10_1161_ATVBAHA_117_310368 wolterskluwer_health_10_1161_ATVBAHA_117_310368 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2018-March |
PublicationDateYYYYMMDD | 2018-03-01 |
PublicationDate_xml | – month: 03 year: 2018 text: 2018-March |
PublicationDecade | 2010 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | Arteriosclerosis, thrombosis, and vascular biology |
PublicationTitleAlternate | Arterioscler Thromb Vasc Biol |
PublicationYear | 2018 |
Publisher | American Heart Association, Inc |
Publisher_xml | – name: American Heart Association, Inc |
References | e_1_3_4_3_2 e_1_3_4_2_2 e_1_3_4_9_2 e_1_3_4_8_2 e_1_3_4_7_2 e_1_3_4_6_2 e_1_3_4_5_2 e_1_3_4_4_2 e_1_3_4_22_2 e_1_3_4_23_2 e_1_3_4_20_2 e_1_3_4_21_2 e_1_3_4_26_2 e_1_3_4_27_2 e_1_3_4_24_2 e_1_3_4_25_2 e_1_3_4_28_2 e_1_3_4_29_2 e_1_3_4_30_2 e_1_3_4_11_2 e_1_3_4_12_2 e_1_3_4_32_2 e_1_3_4_10_2 e_1_3_4_31_2 e_1_3_4_15_2 e_1_3_4_16_2 e_1_3_4_13_2 e_1_3_4_14_2 e_1_3_4_19_2 e_1_3_4_17_2 e_1_3_4_18_2 |
References_xml | – ident: e_1_3_4_11_2 doi: 10.1161/STROKEAHA.113.001461 – ident: e_1_3_4_13_2 doi: 10.1001/jama.1987.03390230069027 – ident: e_1_3_4_8_2 doi: 10.1016/j.amjcard.2014.08.001 – ident: e_1_3_4_23_2 doi: 10.1161/ATVBAHA.112.251306 – ident: e_1_3_4_7_2 doi: 10.1016/j.jacc.2013.06.051 – ident: e_1_3_4_6_2 doi: 10.1161/STROKEAHA.111.624684 – ident: e_1_3_4_32_2 doi: 10.1194/jlr.R052258 – ident: e_1_3_4_15_2 doi: 10.1056/NEJMoa011090 – ident: e_1_3_4_14_2 doi: 10.1056/NEJM199011083231901 – ident: e_1_3_4_16_2 doi: 10.7326/0003-4819-142-2-200501180-00008 – ident: e_1_3_4_12_2 doi: 10.1161/STROKEAHA.114.005752 – ident: e_1_3_4_3_2 doi: 10.1093/eurheartj/ehq386 – ident: e_1_3_4_4_2 doi: 10.1161/CIRCULATIONAHA.107.715698 – ident: e_1_3_4_17_2 doi: 10.1016/j.jacc.2010.03.017 – ident: e_1_3_4_21_2 doi: 10.1001/jama.2009.1063 – ident: e_1_3_4_27_2 doi: 10.1016/j.atherosclerosis.2017.06.026 – ident: e_1_3_4_22_2 doi: 10.1056/NEJMoa0902604 – ident: e_1_3_4_9_2 doi: 10.1016/j.atherosclerosis.2015.11.032 – ident: e_1_3_4_29_2 doi: 10.1056/NEJMoa1501031 – ident: e_1_3_4_25_2 doi: 10.1194/jlr.P030890 – ident: e_1_3_4_30_2 doi: 10.1056/NEJMoa1615664 – ident: e_1_3_4_2_2 doi: 10.1161/01.CIR.102.10.1082 – ident: e_1_3_4_18_2 doi: 10.1161/01.CIR.0000148955.19792.8D – ident: e_1_3_4_31_2 doi: 10.1038/ncpcardio1456 – ident: e_1_3_4_26_2 doi: 10.1194/jlr.M040733 – ident: e_1_3_4_28_2 doi: 10.1056/NEJMoa1500858 – ident: e_1_3_4_24_2 doi: 10.2217/clp.13.9 – ident: e_1_3_4_19_2 doi: 10.1016/j.amjcard.2014.01.426 – ident: e_1_3_4_20_2 doi: 10.1001/jama.2016.16951 – ident: e_1_3_4_5_2 doi: 10.1001/jama.2009.801 – ident: e_1_3_4_10_2 doi: 10.1056/NEJMoa1107579 |
SSID | ssj0004220 |
Score | 2.4343972 |
Snippet | OBJECTIVE—To assess whether Lp(a) (lipoprotein(a)) levels and other lipid levels were predictive of progression of atherosclerosis burden as assessed by... To assess whether Lp(a) (lipoprotein(a)) levels and other lipid levels were predictive of progression of atherosclerosis burden as assessed by carotid magnetic... |
SourceID | proquest pubmed crossref wolterskluwer |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 673 |
SubjectTerms | Adult Aged Aged, 80 and over Biomarkers - blood Carotid Arteries - diagnostic imaging Carotid Arteries - drug effects Carotid Arteries - pathology Carotid Artery Diseases - blood Carotid Artery Diseases - diagnostic imaging Carotid Artery Diseases - drug therapy Carotid Artery Diseases - pathology Cholesterol, LDL - blood Double-Blind Method Female Humans Hypolipidemic Agents - therapeutic use Lipoprotein(a) - blood Magnetic Resonance Angiography Male Middle Aged Plaque, Atherosclerotic Predictive Value of Tests Risk Factors Time Factors Treatment Outcome |
Title | Lp(a) (Lipoprotein(a)) Levels Predict Progression of Carotid Atherosclerosis in Subjects With Atherosclerotic Cardiovascular Disease on Intensive Lipid Therapy: An Analysis of the AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Outcomes) Carotid Magnetic Resonance Imaging Substudy—Brief Report |
URI | https://www.ncbi.nlm.nih.gov/pubmed/29301785 https://www.proquest.com/docview/1989538011 |
Volume | 38 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Zb9NAEF7aIiEQQtyES4PEQ6vIbXzG6Zt7kYDTgppA3ywf69bQOqFJVMG_4Z8ys7s-klZV4cVKnHh3vTvf7szuNzOMvUczupOGlqFFphNqVppwzU2MjhYZ3KblwkqFl2t_3-kOrY9H9tHS8p8aa2k2jdbj31f6lfzPqOI9HFfykv2HkS0LxRv4GccXrzjCeL3RGPtj1A9DYdgbrp-NRyLqApn64i794BMpaEJMiySLp-QXcCyZr7n0zMIHsqTpkRo4mmDxeM0ERRZnlO-C6fGNdmrrf6AQr9vzNNYdecxDJw8VJ57SYidE6aCwBWoDsh4DRTi19Ppat_ehSy8g66C8DWeRaEVvgY_Z51MUWYrKfajiLMjG-aOLZnfHx34k1kpzcJ4dn_6KcQASSfjrKU9QGT9ERVPG5w5mUxwVmic7ZU_0w-Oc_DrFuUYu_Cl6ZzKTE82xFIxX2zrPeKpMl7py7xE9Nqu6kcS3ep2CJ1t2mop_VW3-j8e88vqv9qQ_n8hN6q0sP6E-LD3yDmfSsSbjFcB_ztROmSrFq2_r6G7FaytWIsPSKJqbXKivuKeWL9OtwdSsrUWOzBFzeY10aI30Bl-3vK5Hh_brlGtOJjeaD0i-fxDsDX0_GOweDZbZbQMtMUoS8ulLLSC_ISKfli0r_NIcfeNyDfO63yWD7h67fzEijsjkh3ARqSl6g4fsgbLQwJNwe8SWeP6Y3ekrDsqTW2f-eDVcg9Ua3vD7GkikgUIa1JAGoxSUfMEC0iDLoUAakDDDAtJgHmmgkAZYaok0EEgDhbRN8HIocEZVY4FQ4AxWF1EGdZRRc0qUQYEy2TBEGSDKNghjMIexTZAIo0ZJhIFEGBQIWyvfv8AXlPgChS-YxxdIfD1lw73dwXZXU0lbtNhAa0ZL221bj8xWkvIU7YfUNHHq5zHxhO04ClFn4I6p206UdloJhXvk3OGJbsRuy7ajRDefsZV8lPMXDMyWm6IF0Ylcx7WSdjtsm-1O1EatI7JS1zYaTC_EKYhVRgNKrHMaiJ0NRw-UCFJGg0CKYIM1y2fGMp7Ptf9-V0hpgMsunaWGOR_NJgFRTVFXRO2owZ5L8S3LQwsK9RzXbrCNOXkOpGv7NfW9vEF9r9jdar54zVam5zP-Bg2jafRWQPMvNcdsdg |
linkProvider | Colorado Alliance of Research Libraries |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Lp%28a%29+%28Lipoprotein%28a%29%29+Levels+Predict+Progression+of+Carotid+Atherosclerosis+in+Subjects+With+Atherosclerotic+Cardiovascular+Disease+on+Intensive+Lipid+Therapy%3A+An+Analysis+of+the+AIM-HIGH+%28Atherothrombosis+Intervention+in+Metabolic+Syndrome+With+Low+HDL%2FHigh+Triglycerides%3A+Impact+on+Global+Health+Outcomes%29+Carotid+Magnetic+Resonance+Imaging+Substudy-Brief+Report&rft.jtitle=Arteriosclerosis%2C+thrombosis%2C+and+vascular+biology&rft.au=Hippe%2C+Daniel+S&rft.au=Phan%2C+Binh+An+P&rft.au=Sun%2C+Jie&rft.au=Isquith%2C+Daniel+A&rft.date=2018-03-01&rft.issn=1524-4636&rft.eissn=1524-4636&rft.volume=38&rft.issue=3&rft.spage=673&rft_id=info:doi/10.1161%2FATVBAHA.117.310368&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1079-5642&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1079-5642&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1079-5642&client=summon |